Back to Journals » OncoTargets and Therapy » Volume 7

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

Total article views   Abstract views HTML views PDF downloads Totals
6,416 Dovepress* 4,560 1,161+ 1,091 5,721
PubMed Central* 0 695 335 695
Totals 4,560 1,856 1,426 6,416
*Since 26 September 2014
+Since July 2016

View citations on PubMed Central and Google Scholar